| hsa05417 |
lipid and atherosclerosis |
24 |
215 |
4.88 × 10–15
|
hsa04020 |
calcium signaling pathway |
12 |
240 |
3.49 × 10–4
|
| hsa05200 |
pathways in cancer |
31 |
531 |
5.72 × 10–12
|
hsa04520 |
adherens junction |
7 |
71 |
3.54 × 10–4
|
| hsa05215 |
prostate cancer |
15 |
97 |
2.82 × 10–11
|
hsa05169 |
Epstein–Barr virus infection |
11 |
202 |
3.56 × 10–4
|
| hsa05205 |
proteoglycans in
cancer |
18 |
205 |
1.44 × 10–9
|
hsa05218 |
melanoma |
7 |
72 |
3.82 × 10–4
|
| hsa04151 |
PI3K-Akt signaling pathway |
22 |
354 |
6.42 × 10–9
|
hsa04115 |
p53 signaling pathway |
7 |
73 |
4.12 × 10–4
|
| hsa04210 |
apoptosis |
14 |
136 |
2.64 × 10–8
|
hsa05165 |
human papillomavirus infection |
14 |
331 |
4.50 × 10–4
|
| hsa05161 |
hepatitis B |
15 |
162 |
2.71 × 10–8
|
hsa04660 |
T-cell receptor
signaling pathway |
8 |
104 |
4.64 × 10–4
|
| hsa04657 |
IL-17 signaling pathway |
12 |
94 |
4.06 × 10–8
|
hsa04910 |
insulin signaling pathway |
9 |
137 |
4.77 × 10–4
|
| hsa04933 |
AGE-RAGE signaling pathway in
diabetic complications |
12 |
100 |
7.78 × 10–8
|
hsa04659 |
Th17 cell differentiation |
8 |
108 |
5.83 × 10–4
|
| hsa01521 |
EGFR tyrosine kinase inhibitor resistance |
11 |
79 |
8.12 × 10–8
|
hsa05152 |
tuberculosis |
10 |
180 |
6.59 × 10–4
|
| hsa04926 |
relaxin signaling pathway |
13 |
129 |
1.27 × 10–7
|
hsa04621 |
NOD-like receptor signaling
pathway |
10 |
184 |
7.72 × 10–4
|
| hsa05010 |
Alzheimer disease |
21 |
384 |
1.36 × 10–7
|
hsa04670 |
leukocyte transendothelial
migration |
8 |
114 |
8.06 × 10–4
|
| hsa05163 |
human cytomegalovirus infection |
16 |
225 |
2.66 × 10–7
|
hsa04215 |
apoptosis—multiple species |
5 |
32 |
8.19 × 10–4
|
| hsa05418 |
fluid shear stress and atherosclerosis |
13 |
139 |
2.90 × 10–7
|
hsa05134 |
legionellosis |
6 |
57 |
9.44 × 10–4
|
| hsa05223 |
non-small cell lung cancer |
10 |
72 |
4.17 × 10–7
|
hsa05213 |
endometrial cancer |
6 |
58 |
1.02 × 10–3
|
| hsa01522 |
endocrine resistance |
11 |
98 |
6.39 × 10–7
|
hsa04071 |
sphingolipid signaling pathway |
8 |
119 |
1.04 × 10–3
|
| hsa04914 |
progesterone-mediated oocyte
maturation |
11 |
102 |
9.29 × 10–7
|
hsa04935 |
growth hormone synthesis, secretion, and action |
8 |
119 |
1.04 × 10–3
|
| hsa04625 |
C-type lectin receptor signaling
pathway |
11 |
104 |
1.11 × 10–6
|
hsa04722 |
neurotrophin signaling pathway |
8 |
119 |
1.04 × 10–3
|
| hsa04931 |
insulin resistance |
11 |
108 |
1.58 × 10–6
|
hsa04014 |
Ras signaling pathway |
11 |
232 |
1.05 × 10–3
|
| hsa04066 |
HIF-1 signaling pathway |
11 |
109 |
1.72 × 10–6
|
hsa04932 |
non-alcoholic fatty liver disease |
9 |
155 |
1.08 × 10–3
|
| hsa04915 |
estrogen signaling pathway |
12 |
138 |
2.07 × 10–6
|
hsa04217 |
necroptosis |
9 |
159 |
1.27 × 10–3
|
| hsa04668 |
TNF signaling pathway |
11 |
112 |
2.21 × 10–6
|
hsa04611 |
platelet activation |
8 |
124 |
1.32 × 10–3
|
| hsa05145 |
toxoplasmosis |
11 |
112 |
2.21 × 10–6
|
hsa05203 |
viral carcinogenesis |
10 |
204 |
1.60 × 10–3
|
| hsa05162 |
measles |
12 |
139 |
2.22 × 10–6
|
hsa05132 |
Salmonella infection |
11 |
249 |
1.79 × 10–3
|
| hsa05235 |
PD-L1 expression and PD-1 checkpoint pathway in cancer |
10 |
89 |
2.58 × 10–6
|
hsa05164 |
Influenza A |
9 |
171 |
2.02 × 10–3
|
| hsa05415 |
diabetic cardiomyopathy |
14 |
203 |
2.79 × 10–6
|
hsa04664 |
Fc epsilon RI signaling pathway |
6 |
68 |
2.09 × 10–3
|
| hsa05120 |
epithelial cell signaling in Helicobacter pylori infection |
9 |
70 |
3.78 × 10–6
|
hsa04920 |
adipocytokine signaling pathway |
6 |
69 |
2.23 × 10–3
|
| hsa05022 |
pathways of neurodegeneration—multiple diseases |
21 |
476 |
4.04 × 10–6
|
hsa05230 |
central carbon metabolism in cancer |
6 |
70 |
2.38 × 10–3
|
| hsa05207 |
chemical carcinogenesis—receptor activation |
14 |
212 |
4.52 × 10–6
|
hsa05206 |
MicroRNAs in cancer |
12 |
310 |
2.81 × 10–3
|
| hsa05133 |
pertussis |
9 |
76 |
7.06 × 10–6
|
hsa05140 |
leishmaniasis |
6 |
77 |
3.61 × 10–3
|
| hsa05167 |
Kaposi sarcoma-associated herpesvirus
infection |
13 |
194 |
9.89 × 10–6
|
hsa04072 |
phospholipase D signaling pathway |
8 |
148 |
3.62 × 10–3
|
| hsa04370 |
VEGF signaling pathway |
8 |
59 |
1.22 × 10–5
|
hsa05226 |
gastric cancer |
8 |
149 |
3.75 × 10–3
|
| hsa04510 |
focal adhesion |
13 |
201 |
1.42 × 10–5
|
hsa04726 |
serotonergic synapse |
7 |
115 |
4.33 × 10–3
|
| hsa05219 |
bladder cancer |
7 |
41 |
1.54 × 10–5
|
hsa04150 |
mTOR signaling pathway |
8 |
156 |
4.83 × 10–3
|
| hsa04936 |
alcoholic liver disease |
11 |
142 |
1.86 × 10–5
|
hsa04010 |
MAPK signaling pathway |
11 |
294 |
5.87 × 10–3
|
| hsa05222 |
small cell lung cancer |
9 |
92 |
2.92 × 10–5
|
hsa04540 |
gap junction |
6 |
88 |
6.37 × 10–3
|
| hsa04152 |
AMPK signaling pathway |
10 |
120 |
3.01 × 10–5
|
hsa00591 |
linoleic acid metabolism |
4 |
29 |
6.62 × 10–3
|
| hsa04912 |
GnRH signaling pathway |
9 |
93 |
3.16 × 10–5
|
hsa04650 |
natural killer cell-mediated
cytotoxicity |
7 |
126 |
6.74 × 10–3
|
| hsa04919 |
thyroid hormone signaling pathway |
10 |
121 |
3.21 × 10–5
|
hsa00590 |
arachidonic acid metabolism |
5 |
61 |
8.83 × 10–3
|
| hsa05208 |
chemical carcinogenesis—reactive
oxygen species |
13 |
223 |
3.99 × 10–5
|
hsa04024 |
cAMP signaling pathway |
9 |
221 |
9.42 × 10–3
|
| hsa04613 |
neutrophil extracellular trap formation |
12 |
190 |
4.38 × 10–5
|
hsa04750 |
inflammatory
mediator regulation of TRP channels |
6 |
98 |
9.95 × 10–3
|
| hsa05160 |
hepatitis C |
11 |
157 |
4.42 × 10–5
|
hsa04371 |
apelin signaling pathway |
7 |
139 |
1.07 × 10–2
|
| hsa01524 |
platinum drug resistance |
8 |
73 |
5.00 × 10–5
|
hsa05146 |
amebiasis |
6 |
102 |
1.17 × 10–2
|
| hsa05171 |
coronavirus disease—COVID-19 |
13 |
232 |
5.87 × 10–5
|
hsa05017 |
spinocerebellar ataxia |
7 |
143 |
1.22 × 10–2
|
| hsa05214 |
glioma |
8 |
75 |
5.96 × 10–5
|
hsa05221 |
acute myeloid leukemia |
5 |
67 |
1.22 × 10–2
|
| hsa04068 |
FoxO signaling pathway |
10 |
131 |
6.02 × 10–5
|
hsa04064 |
NF-kappa B signaling pathway |
6 |
104 |
1.26 × 10–2
|
| hsa05130 |
pathogenic Escherichia coli infection |
12 |
197 |
6.10 × 10–5
|
hsa04620 |
toll-like receptor signaling
pathway |
6 |
104 |
1.26 × 10–2
|
| hsa05142 |
chagas disease |
9 |
102 |
6.16 × 10–5
|
hsa04960 |
aldosterone-regulated sodium
reabsorption |
4 |
37 |
1.30 × 10–2
|
| hsa05212 |
pancreatic cancer |
8 |
76 |
6.49 × 10–5
|
hsa05204 |
chemical carcinogenesis—DNA
adducts |
5 |
69 |
1.35 × 10–2
|
| hsa05020 |
prion disease |
14 |
273 |
6.68 × 10–5
|
hsa05224 |
breast cancer |
7 |
147 |
1.38 × 10–2
|
| hsa05225 |
hepatocellular carcinoma |
11 |
168 |
7.85 × 10–5
|
hsa05202 |
transcriptional misregulation
in cancer |
8 |
193 |
1.47 × 10–2
|
| hsa05135 |
Yersinia infection |
10 |
137 |
8.53 × 10–5
|
hsa04921 |
oxytocin signaling
pathway |
7 |
154 |
1.71 × 10–2
|
| hsa04140 |
autophagy—animal |
10 |
141 |
1.07 × 10–4
|
hsa04630 |
JAK-STAT signaling pathway |
7 |
162 |
2.13 × 10–2
|
| hsa05131 |
Shigellosis |
13 |
247 |
1.07 × 10–4
|
hsa04810 |
regulation of actin cytoskeleton |
8 |
218 |
2.67 × 10–2
|
| hsa04015 |
Rap1 signaling pathway |
12 |
210 |
1.08 × 10–4
|
hsa04380 |
osteoclast differentiation |
6 |
128 |
2.83 × 10–2
|
| hsa05170 |
human immunodeficiency virus 1 infection |
12 |
212 |
1.18 × 10–4
|
hsa05032 |
morphine addiction |
5 |
91 |
3.34 × 10–2
|
| hsa04012 |
ErbB signaling pathway |
8 |
85 |
1.33 × 10–4
|
hsa04614 |
renin–angiotensin system |
3 |
23 |
3.74 × 10–2
|
| hsa05210 |
colorectal cancer |
8 |
86 |
1.43 × 10–4
|
hsa04923 |
regulation
of lipolysis in adipocytes |
4 |
56 |
3.88 × 10–2
|
| hsa04360 |
axon guidance |
11 |
182 |
1.53 × 10–4
|
hsa04550 |
signaling pathways regulating pluripotency of stem cells |
6 |
143 |
4.26 × 10–2
|
| hsa04218 |
cellular senescence |
10 |
156 |
2.30 × 10–4
|
hsa04062 |
chemokine signaling pathway |
7 |
192 |
4.37 × 10–2
|
| hsa05231 |
choline metabolism in cancer |
8 |
98 |
3.23 × 10–4
|
hsa04723 |
retrograde
endocannabinoid signaling |
6 |
148 |
4.82 × 10–2
|
| hsa04917 |
prolactin signaling
pathway |
7 |
70 |
3.28 × 10–4
|
hsa04213 |
longevity regulating pathway—multiple
species |
4 |
62 |
5.00 × 10–2
|
| hsa04930 |
type II diabetes mellitus |
6 |
46 |
3.47 × 10–4
|
|
|
|
|
|
